Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Efficacy of H1N1 Vaccines in Children
NCT01051661Phase 3Completed
- Sponsor
- GSK
- Start
- Feb 2010
- Primary completion
- Aug 2011
- Modality
- Split/Subunit Vaccines, Recombinant Protein Vaccines, Cancer Vaccines
- Countries
- 8
01
Overview
Phase 3, randomised, double-blind trial of recombinant influenza ha vaccine (h5n1) and GSK2340273A in influenza A H1N1 infection (H1N1) (6 arms), sponsored by GSK. Primary endpoint: Number of Subjects Reporting at Least One A/California Influenza Event. Started Feb 2010; status: completed.
02
Drugs
recombinant influenza ha vaccine (h5n1)GSK2340273A
03
Conditions
influenza A H1N1 infection (H1N1)
Beyond the preview
Go deeper on NCT01051661.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01051661.